Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMCI + Nivolumab + SOC in Newly Diagnosed High-Grade Gliomas
NCT03576612Phase 1Completed
- Sponsor
- Candel Therapeutics
- Start
- Feb 2018
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of aglatimagene besadenovec in glioma (2 cohorts), sponsored by Candel Therapeutics. Primary endpoints: Incidence of adverse events up to 2 years and Maximum Tolerated Dose up to 2 years. Started Feb 2018; status: completed.
02
Drugs
aglatimagene besadenovec
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03576612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576612.